July/August 1999

Vol 6, No 4 CME Pretest

This Journal provides 4 hours of Category 1 Continuing Medical Education

Complimentary CME Credits

Physicians can earn 4 credit hours of Category 1 for the Physician's Recognition Award of the American Medical Association by reading the material in this issue and successfully answering the questions in the posttest at the end of this issue. Complete instructions are given on the posttest pages. Successfully answering 30 or more questions will earn 4 credit hours. CME is presented by an unrestricted educational grant from Bristol-Myers Squibb Oncology Division.

Educational Objectives

After reading this issue of Cancer Control, clinicians will be expected to:

• understand the genetic basis of ovarian cancer
• appreciate the potential of vaccines in ovarian cancer,
• recommend concomitant cisplatin-based chemotherapy and radiation for cervic cancer, and
• assess the role of taxanes in treating gastric cancer.

Release Date: July 1, 1999
Expiration Date: July 1, 2000

Pretest

1. The risk of ovarian carcinoma by 70 years of age for most patients with BRCA2 mutations is currently estimated to be:

a. 27%

b. 31%

c. 38%

d. 47%

2. Approximately what proportion of patients with late-stage ovarian cancer will have metastases involving the peritoneum or serosa of abdominal organs?

a. 80%

b. 85%

c. 90%

d. 95%

3. Patients with advanced gastric cancer who are given the FAM regimen (5-fluorouracil, doxorubicin, and mitomycin C) experience what effect on survival?

a. longer survival

b. shorter survival

c. unknown

d. no effect